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Background
There is a growing interest in using cognitive–behavioural
therapy (CBT) with people who have Asperger syndrome
and comorbid mental health problems.
Aims
To examine whether modified group CBT for clinically
significant anxiety in an Asperger syndrome population
is feasible and likely to be efficacious.
Method
Using a randomised assessor-blind trial, 52 individuals with
Asperger syndrome were randomised into a treatment arm
or a waiting-list control arm. After 24 weeks, those in the
waiting-list control arm received treatment, while those
initially randomised to treatment were followed up for
24 weeks.
Results
The conversion rate for this trial was high (1.6:1), while attrition
was 13%. After 24 weeks, there was no significant difference
between those randomised to the treatment arm comparedwith
those randomised to the waiting-list control arm on the primary
outcome measure, the Hamilton Rating Scale for Anxiety.
Conclusions
Trials of psychological therapies with this population are
feasible. Larger definitive trials are now needed.
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Anxiety disorders and related symptomatology are commonly
found among those with autistic spectrum disorders (ASDs),
including Asperger syndrome.1–7 A meta-analysis examining the
effectiveness of cognitive–behavioural therapy (CBT) for anxiety
disorders in children with ASDs reported that treatment had an
effect size of d=1.19 for clinician-rated outcome measures, d=1.21
for parent-rated outcome measures and d=0.68 for child self-
report outcome measures.8 The literature about the treatment of
mental health problems for adults with ASDs using CBT remains
relatively sparse; there have been some case studies9,10 and some
small trials.11–14 The aim of this trial was to collect data sufficient
to inform the design of a definitive large-scale trial. The specific
objectives included (a) assessing whether a CBT intervention is
likely to be efficacious within a pilot, assessor-blind RCT with
adults who have Asperger syndrome experiencing problems with
anxiety, and (b) to gain participant views about taking part in
therapy.
Method
Participants
Fifty-two individuals, Mage=35.9, s.d.=14.5, 48% women, were
recruited and enrolled within the trial from Kent, South East London
and Norfolk within the UK. Recruitment took place within the
community from Asperger syndrome/autism teams, Asperger syn-
drome user groups, such as Asperger East Anglia, the Kent Autistic
Trust, Bridging the Gap, the Disability and Dyslexia Support Services
at the University of Kent, intellectual disability teams, adult mental
health teams, and through public advertisements. Participant flow
throughout the trial is found in Fig. 1, and further demographic
information can be found in Table 1.
All participants were initially screened by research workers
to determine eligibility to take part in the trial. The inclusion
criteria were as follows: (a) participants fulfilled diagnostic criteria
for Asperger syndrome, high-functioning autism or pervasive
developmental disorder – not specified; diagnosis was confirmed
by inspection of previous records, or the study team used the
Autism Diagnostic Observation Schedule to confirm the diagnosis;
(b) participants had clinically significant difficulties with anxiety
as confirmed through the use of the Hamilton Rating Scale for
Anxiety (HAM-A; score of >14 qualified inclusion); (c) participants
were between 16 and 65 years of age; (d) full Scale IQ>70 on the
Wechsler Abbreviated Scale of Intelligence.15 The exclusion criteria
were as follows: (a) participants with post-traumatic stress disorder,
or anxiety related to substance misuse; (b) comorbid severe
psychiatric disorders that impair capacity to consent to take part
(e.g. florid symptoms of psychosis); and (c) current substance
misuse such as alcohol or drugs.
Design and randomisation
This study was an assessor-blind randomised trial. Our full
protocol has been published elsewhere.16 Masked researchers
enrolled participants and carried out the assessments. Even pairs
of participants were allocated to the treatment arm (group CBT+
treatment as usual (TAU) for 24 weeks) or the waiting-list control
arm (TAU for 24 weeks) using blocked randomisation with random
even blocks, stratified by study site. The therapists at each research
site contacted participants to inform them of their group allocation.
All data were stored independently by the Norwich Clinical Trials
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Unit based at the University of East Anglia, who also carried out
randomisation. Once randomisation had been completed, thera-
pists were informed, who then informed participants.
After the initial 24 weeks of treatment, those within the waiting-
list control group received 24 weeks of group CBT, while those who
had already taken part in group CBT continued to receive TAU for a
further 24 weeks. Both groups were assessed again following this
further 24-week period. This allowed for 50% of the participants,
those who received treatment first, to be followed up for a 6-month
period. Following the completion of all study outcome measures,
participants were interviewed and invited to give their opinions on
the intervention and asked to make suggestions about what they
would like to change. Participants completed the outcome measures
on three occasions: (a) baseline, (b) follow-up 1 and (c) follow-up 2.
Ethical considerations
A favourable ethical opinion was obtained from the Cambridge-
shire 4 NHS Research Ethics Committee (ref.: 10/H0305/42).
Informed consent was sought from participants and their carers,
who completed the Social/Emotional Functioning Interview –
Informant Version. Participants were afforded time to consider
whether they wanted to participate and were given the opportu-
nity to ask any questions. Information about the study was
provided in an ‘easier to read’ format for participants who may
have had reading difficulties. Participants were told that they
could withdraw from the trial at any stage without giving a reason,
and this would not affect access to other treatments or services.
Adverse events relating to the trial were monitored throughout
and none was detected.
Assessed for eligibility (n=83)
Excluded (n=15)
♦ Not meeting inclusion criteria (n=8)
♦ Declined to participate (n=4)
♦ Exclusion criterion met (n=1)
♦ Dropped out (n=1)
♦ Chose to receive therapy elsewhere (n=1)
Allocated to Waiting List (n=23)
♦ withdrawn (n=3)
Allocated to Treatment (n=26)
♦ withdrawn (n=1)
Allocated to Waiting List (n=26)
Allocated to Treatment  (n=25)
Allocation
Follow-Up 1
(n=48)
Randomized (n=52)
Enrollment Declined to Participate (n=16)
Baseline Assessment
(n=52)
♦ withdrawn (n=2) ♦ withdrawn (n=1)
Follow-Up 2
(n=45)
Fig. 1 Consort diagram depicting participant ﬂow throughout the trial.
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Intervention
The intervention used within this study comprised 24 weekly
sessions, each lasting approximately 1 h. Participants received three
initial sessions of 1:1 CBT, followed by 21 group CBT sessions. All
sessions took placed within community-based settings. The initial
three sessions of therapy aimed to help socialise each participant
into CBT and to address any concerns they may have about joining
the group. At least two therapists were present for each group
session. In order to ensure adherence to treatment, a treatment
manual17 was developed with specific aims for each session, and all
sessions were delivered by a registered clinical psychologist or a
qualified cognitive–behavioural therapist. The treatment manual
included the following topics: (a) psychoeducation about ASDs
and anxiety, (b) cognitive restructuring, (c) anxiety management
techniques, (d) systematic desensitisation, (e) exposure to feared
social situations and (f) social skills training. These skills were
practiced in vivo. In addition to the intervention, participants in
both arms before and after crossover received TAU. The descrip-
tion of our intervention is intentionally brief within this paper as
the complete treatment manual, which includes all session-by-
session contents, can be downloaded from http://www.kent.ac.uk/
tizard/staff/acadstaff/pete_langdon.html.
Outcome measures and analysis
Our primary outcome measure was the HAM-A. Data were
collected at participants’ homes, the university or in community-
based clinical settings.
Primary outcome measure
1. Hamilton Rating Scale for Anxiety. This is a structured
clinician-rated scale incorporating 14 factors which are considered
valid indicators of anxiety.18 Each factor reflects a symptom
of anxiety; physical as well as mental symptoms are represented.
The factors are scored on a 5-point scale as part of a structured
interview.
Secondary outcome measures
1. Social Phobia Inventory. This is a 17-item self-report measure of
behavioural, physiological and cognitive symptoms associated
with social phobia.19 Participants rate the frequency with which
they experience each symptom over the last week, using a 5-point
Likert-type scale (0–4).
2. Liebowitz Social Anxiety Scale. This instrument is a self-report
scale that assesses fear and avoidance throughout 24 listed
situations, which are likely to elicit social anxiety.20
3. Social and Emotional Functioning Interview (Informant and
Subject Versions). This is a semi-structured clinician-rated assess-
ment of everyday social and psychiatric functioning that was
designed to assess independence, leisure, interpersonal problems,
employment and social relationships.21 Some items are shared
with the Autistic Diagnostic Observation Schedule. This measure
was completed with each participant and a nominated informant.
4. Social Interaction Anxiety Scale. A self-report 20-item measure
of anxiety as experienced in social situations associated with
social anxiety and social phobia in accordance to the DSM-IV
criteria.22,23 Experiences are rated on a 5-point scale from 0 (not at
all characteristic of me) to 4 (extremely characteristic of me).
5. Fear Questionnaire. A self-report questionnaire regarding the
individual perception of fears and phobias; respondents are asked
how likely they are to avoid each of the listed situations, due to
anxiety/fear or any other unpleasant feelings.24 In addition to the
15 pre-existing items the individual is asked to document and
score any individual phobias they would wish treated.
6. Hamilton Rating Scale for Depression. This structured clinician-
rated interview is considered a valid indicator of depression and
the ratings are based on the interviewer’s objective and subjective
perceptions during the assessment.25 Eight items are scored on a
0 (not present) to 4 (severe) point scale, and nine items are scored
from 0 to 2 (levels of severity).
Table 1 Baseline characteristics
Group
Treatment arm (n=26) Waiting list (n=26) Combined (n=52)
Age, years: mean (s.d.) range 33.1 (14.6) 20–64 38.7 (14.3) 17–65 35.9 (14.6) 17–65
Male, n (%) 12 (46) 15 (58) 27 (52)
Female, n (%) 14 (54) 11 (42) 25 (48)
IQ: mean (s.d.) range 106.18 (17.14) 71.00–135.00 104.83 (11.51) 74.00–128.00 105.51 (14.33) 71.00–135.00
Ethnicity, n (%)
White British 25 (96) 26 (100) 51 (98)
White other 1 (4) 0 1 (2)
Marital status, n (%)
Single 19 (73%) 17 (65) 36 (69)
Cohabiting 0 2 (8) 2 (4)
Married 4 (15%) 5 (19) 9 (17)
Divorced 3 (12%) 2 (8) 5 (10)
Children, n (%)
None 20 (77) 20 (77) 40 (77)
1 0 2 (8) 2 (4)
2 2 (8) 3 (12) 5 (10)
3 4 (15) 0 4 (8)
>3 0 1 (4) 1 (2)
Education
Primary 1 (4) 0 1 (2)
Secondary 7 (27) 9 (35) 16 (31)
Tertiary 8 (31) 9 (35) 17 (33)
University degree 10 (38) 8 (31) 18 (35)
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Views about therapy. Following the completion of the trial,
participants were interviewed, and asked to rate nine questions on
a 5-point Likert Scale about their experiences of receiving therapy.
Participants were also asked the five following questions, with
supplementary questions used for clarification: (1) ‘What were
you hoping for by taking part in this research study?’, (2) ‘What
was best about the group?’, (3) ‘What was worst about the group?’,
(4) ‘What advice would you give for the next group?’ and (5)
‘Were there any difficulties you feel that the group did not
address?’.
Health economics. Generic health-related quality of life (EuroQol
EQ-5D) and health service contact data were also collected. These
will be reported separately (manuscript in preparation) and
includes some description of TAU.
Analysis
Data were analysed using SAS Version 9.4 by a statistician (L.S.)
masked to subgroup, controlling for baseline scores, making use of
the intention-to-treat principle; the analysis was completed using
the originally assigned groups. The initial group allocation for
participants did not change throughout the trial. Data about
participants’ views of taking part in therapy were subjected to
both a frequency and descriptive thematic analysis. A supplemen-
tary analysis was completed using participants who attended at
least 50% of the treatment sessions at follow-up 1 in order to
examine whether outcomes were different for those who attended
a greater number of sessions.
Results
Considering recruitment, 83 participants were approached and
52 were enrolled; this is a conversion rate of 1.6 participants to
1 participant. In the course of the trial, seven participants were
lost, representing an attrition rate of 13%. One participant told us
that they withdrew because they found travelling to the group
too difficult. Another three participants said that they no longer
wanted to attend the group because it was either too difficult for
them or something they found unhelpful. The other participants
did not respond to our attempts to contact them.
The two treatment arms were well matched on IQ, age, gender
and the primary outcome measure (Tables 1 and 2). Both groups
scored in the ‘mild to moderate’ or ‘moderate to severe’ ranges on
the HAM-A. Participants were predominately White British,
single and without children (Table 1). The two groups did not
differ significantly in terms of the number of treatment sessions
they attended, t (50)≤1, P=0.774 (Table 2).
Turning to consider the primary outcome measure, HAM-A
mean scores significantly improved over time, regardless of
arm, and regardless of baseline scores, F(2,84)=43.67, P<0.001.
Controlling for baseline scores, there was no significant difference
between the treatment and wait list arms at either follow-up 1 or 2
on the HAM-A (Table 2).
Considering the secondary outcome measures, there was a
significant improvement over time, regardless of arm, and baseline
scores, on the Hamilton Rating Scale for Depression (HAM-D),
F(2,84)=7.84, P=0.008; Fear Questionnaire Total Phobia Score,
F(2,84)=6.00, P=0.019; Liebowitz Avoidance, F(2,84)=10.52,
P=0.003; Liebowitz Fear/Anxiety, F(2,84)=10.90, P<0.002; Social
Interaction Anxiety Scale, F(2,84)=16.75, P<0.001; Social Phobia
Inventory, F(2,84)=8.15, P=0.007; the Social/Emotional Function-
ing Interview – Informant, F(2,84)=30.87, P<0.001; and Subject
Versions, F(2,84)=17.37, P<0.001 (Table 3). Controlling for
baseline scores, there was no significant difference between the
treatment and wait list arms on any of the secondary outcomes at
follow-up 1 or 2 (Table 3).
Just over half (53%) of the participants agreed or strongly agreed
that the individual sessions that were initially offered helped prepare
them for the group sessions. It was also the case that over half (59%)
of the participants agreed or strongly agreed that they now knew how
to reduce their feelings of anxiety following treatment. However, 38%
of participants thought there was insufficient time during sessions
and 41% thought there were too few sessions. Seventy-nine per cent
of participants agreed or strongly agreed that they found listening to
the problems of others helpful, while nearly 80% agreed or strongly
agreed that they felt supported by other group members. Just over
half (56%) agreed or strongly agreed that therapy reduced their
anxiety, while 44% were neutral, disagreed, or strongly disagreed on
this. Seventy-three per cent of participants agreed or strongly agreed
that they would recommend therapy to others, and 73% agreed or
strongly agreed that therapy was helpful (Table 4).
Turning to consider the open-ended questions that partici-
pants were asked at the end of the trial about their experience
of taking part in therapy, five clear themes emerged which are
largely framed around the questions asked. The first was labelled,
‘motivation to take part’. Participants described taking part in the
trial in order to access help for their mental health problems,
while others had hoped that they might form new relationships
with other people with ASDs. Many told us that they wanted to
‘change their life for the better’ and recognised that anxiety was
having a detrimental effect upon their well-being and ability to
manage their lives.
The second theme was labelled, ‘positive experiences’. Partici-
pants described that they enjoyed ‘interacting with the others;
meant a lot because we could share and listen to each other’. Some
commented on the inherent value of learning that they are ‘not
alone and others have the same problems’. Several talked about
how being in the group helped them to ‘open up more’.
Participants also told us that they ‘enjoyed learning new skills’
which helped them to cope better with difficulties. There was
Table 2 Mean session attendance and primary outcome measure – Hamilton Rating Scale for Anxiety
Group
Treatment arm (n=26),
mean (s.d.)
Waiting list (n=26),
mean (s.d.) Mean difference (95% CI), P Adjusted mean differencea (95% CI), P
Session attendance 13.3 (7.17) 13.9 (7.27) −0.58 (−3.4 to 4.6), 0.774 –
Hamilton Rating Scale for Anxiety
Screening 27.2 (11.23) n=26 25.3 (13.92) n=26 –
Baseline 25.7 (11.99) n=26 22.8 (9.45) n=26 –
Follow-up 1 15.5 (7.91) n=23 16.3 (7.54) n=25 −0.84 (−5.3 to 3.6), 0.708 −2.46 (−5.9 to 1.0), 0.161
Follow-up 2 13.3 (8.57) n=22 13.6 (5.35) n=23 −0.29 (−4.6 to 4.0), 0.892 −0.91 (−5.0 to 3.2), 0.659
aResulting from an ANCOVA including baseline score.
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evidence from some participants that they derived benefit from the
group; one person said, ‘I was pleased to come away with coping
strategies’, while another said, ‘I used to go out seven times in
22 years and now I can go wherever’. Another said that they found
the group, ‘enjoyable and fulfilling’, and some participants talked
about seeking further access to psychological therapies elsewhere
because the trial had finished.
The third theme was labelled, ‘negative experiences’. Many
participants were clear that they wanted to have had longer
sessions. One commented, ‘by the time we open up and talked
about what bothered us … the group stopped’. Some suggested
longer sessions of 90 to 120 min. Others spoke about issues
around the dynamics of being in a group, with one participant
stating, ‘the group could be easily hijacked’. Participants
considered that sometimes their problems were not addressed
because other group members talked more. Others felt that some
group members spoke about ‘irrelevant issues’ and felt that the
therapists should have re-focused the group more frequently.
Several spoke about needing more continuity and greater focus
on making sure the sessions flowed more effectively, while there
were a few participants who commented that they found taking
part in a group very difficult and thought the whole experience
was negative. However, several commented that they could not
think of anything negative about the groups, and several said
that the most negative aspect was ‘ending’ and they ‘missed
the group’.
The fourth theme was labelled, ‘further adaptations’. Partici-
pants described a variety of changes that they would like in order
to improve therapy for the future. This included, ‘more pre-
paratory work’ for those who found groups difficult, and several
suggested that more individual sessions might motivate some
people to change. One person talked about wanting to alternate
between blocks of group sessions and individual sessions. Many
participants recommended that they would like to see longer
sessions in the future which would allow them to consider their
problems in ‘more depth, like depression’ and ‘greater work on
social skills and friendships’. While several said they really
enjoyed homework tasks, some commented that they would like
‘multimedia options, like DVDs, pictures and audio’ for home-
work and during the sessions.
The final theme to emerge was titled, ‘pragmatic issues’.
Participants told us that there were sometimes issues with public
transport, travelling, the timings of the group, heating in the
rooms and difficulties with parking, all of which they did not like.
Supplementary analysis
In order to consider whether there may have been a relationship
between the number of sessions attended and the outcome, those
who had received treatment were split into two subgroups at
follow-up; those who had attended <50% of the treatment sessions
and those who had attended ≥50% of the treatment sessions.
Considering only those participants who had attended ≥50% of
Table 3 Secondary outcome measures: means (standard deviations)
Group
Treatment Waiting list Adjusted mean differencea (95% CI), P
Hamilton Rating Scale – Depression Baseline 20.5 (9.51) 17.5 (8.56)
Follow-up 1 17.5 (8.08) 17.2 (6.61) −1.42 (−4.7 to 1.9), 0.396
Follow-up 2 16.5 (9.68) 13.6 (5.39) 2.09 (−2.4 to 6.6), 0.353
Fear Questionnaire – Total Phobia Baseline 50.9 (20.71) 42.3 (17.48)
Follow-up 1 43.2 (19.20) 36.1 (20.73) −0.66 (−10.1 to 8.8), 0.890
Follow-up 2 43.7 (22.87) 33.4 (21.54) 6.18 (−6.6 to 18.9), 0.338
Fear Questionnaire – Avoidance Baseline 6.1 (2.40) 4.2 (3.16)
Follow-up 1 5.5 (2.79) 4.6 (2.90) 1.68 (−0.0 to 3.4), 0.052
Follow-up 2 5.1 (2.41) 3.5 (2.91) 0.13 (−1.7 to 2.0), 0.890
Fear Questionnaire – Anxiety/Depression Baseline 23.2 (10.03) 20.7 (9.60)
Follow-up 1 21.4 (8.58) 19.1 (9.98) 0.06 (−4.0 to 4.1), 0.977
Follow-up 2 18.4 (9.75) 16.5 (9.25) 1.21 (−4.2 to 6.6), 0.657
Fear Questionnaire – Global Rating Baseline 5.2 (2.23) 4.9 (1.97)
Follow-up 1 3.0 (2.70) 3.8 (2.39) −1.11 (−2.4 to 0.2), 0.094
Follow-up 2 3.5 (2.60) 3.2 (1.92) 0.02 (−1.2 to 1.3), 0.980
Liebowitz avoidance Baseline 42.2 (14.81) 40.3 (13.94)
Follow-up 1 39.2 (14.31) 34.1 (15.77) 1.47 (−5.0 to 8.0), 0.652
Follow-up 2 34.5 (17.61) 28.8 (12.42) 6.40 (−1.5 to 14.3), 0.114
Liebowitz Fear/Anxiety Baseline 43.4 (15.10) 43.4 (13.99)
Follow-up 1 42.2 (12.81) 36.8 (15.66) 3.09 (−2.2 to 9.0), 0.299
Follow-up 2 39.1 (16.33) 31.6 (13.72) 7.33 (−0.8 to 15.5), 0.080
Social Interaction Anxiety Scale Baseline 43.9 (13.56) 42.3 (13.53)
Follow-up 1 41.5 (14.08) 39.8 (16.59) 0.02 (−5.0 to 5.1), 0.994
Follow-up 2 39.8 (14.65) 35.6 (13.22) 3.01 (−3.9 to 9.9), 0.390
Social Phobia Inventory Baseline 34.3 (16.57) 31.6 (16.94)
Follow-up 1 33.0 (14.08) 25.4 (15.84) 4.69 (−1.7 to 11.0), 0.147
Follow-up 2 27.2 (16.20) 24.3 (14.74) 1.99 (−5.9 to 9.9), 0.616
Social/Emotional Functioning Interview – Baseline 57.5 (17.30) 53.8 (17.58)
Informant Version – Total Score Follow-up 1 52.5 (18.52) 51.2 (15.97) −3.22 (−83 to 1.9), 0.210
Follow-up 2 45.6 (16.16) 39.8 (14.78) 3.32 (−3.7 to 10.3), 0.343
Social/Emotional Functioning Interview – Baseline 48.2 (21.22) 47.1 (23.71)
Subject Version – Total Score Follow-up 1 46.0 (18.94) 42.7 (14.41) 1.78 (−3.2 to 6.8), 0.478
Follow-up 2 38.1 (18.00) 31.7 (12.28) 5.96 (−2.9 to 14.8), 0.183
aResulting from an ANCOVA including baseline score.
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the treatment sessions increased the magnitude of difference
between the treatment and waiting-list control arms on the
primary outcome measure at follow-up 1 than that reported using
our per-protocol analysis, although the difference was not
statistically significant (Table 5).
Discussion
The conversion rate within this trial was high, and the attrition
rate was much lower than that reported within other clinical trials
of psychological therapies for anxiety disorders,26 suggesting that
trials in this area are feasible. Nevertheless, the results indicated
that over time, regardless of arm, anxiety symptoms improved
significantly. There are likely to be several reasons for this finding;
the most likely is that as this is a pilot trial, the probability of
making a Type II error had been elevated because of the sample
size. Second, it may have been the case that enrolment within the
trial led to ‘spontaneous recovery’ amongst those randomised to
the waiting list arm. While we did not include a placebo or
attention-control condition within this trial, there is evidence that
the placebo response has a greater effect within smaller trials.27 All
of the participants in our trial were told to expect treatment, and
for one-half of them, they were told that this treatment would be
delayed by 6 months. Over this 6-month period, by instilling a
sense of hope and expectation, a placebo response could have
occurred, resulting in a reduction in symptoms. Interestingly,
Wampold et al28 reanalysed the data used in a previous meta-
analysis investigating placebo effects within trials.27 They reported
no differences between the effect size associated with the treat-
ment and placebo arms within trials when a disorder was (1) likely
to be affected by psychological factors and (2) investigated using a
robust methodology. Third, it is important to consider that we did
not stop any ongoing or existing treatments for those participants
randomised to the waiting list arm. It may have been the case
that TAU led to a significant reduction in symptoms for those
participants randomised to the waiting list arm. Fourth, partici-
pants on average attended 13.6 treatment sessions. It may be the
case that participants did not receive a sufficient dose of the
intervention, and combined with the sample size, significant
treatment effects were therefore not observed. Further, it could
also be the case that treatment was not effective. However, all of
this must be balanced against the fact that this was a pilot trial, as
opposed to a definitive trial, and conclusions regarding treatment
effectiveness are therefore premature. Our supplementary analysis
suggested that there may be a relationship between the number of
treatment sessions attended and outcome, although once again,
such a conclusion is highly tentative considering the nature of this
pilot trial. It is possible that those who attended <50% of the
treatment sessions had greater difficulties with anxiety and found
the group intervention more challenging.
The interviews with participants led to a wealth of information
about the intervention that is useful for future trials. First and
foremost, while a majority of participants reported that they found
the intervention useful, and enjoyed attending the groups, they
also told us that the sessions were too short. When providing
psychological interventions for people who have ASDs, it is
important to ensure that participants have sufficient time to engage
meaningfully within the intervention, considering their informa-
tion processing difficulties. Within the context of group-based
interventions, therapists need to make sure that they manage and
balance the needs of the group, and the needs of individual
members, sufficiently. Based on our findings, we would recom-
mend group sessions last at least 2 h. Second, participants made
several suggestions for adapting psychological therapies further,
which again should be considered by both researchers and
clinicians working in this area. Participants indicated they may
benefit from more individual sessions, and the suggestion to
alternate between blocks of both group and individual sessions
might improve treatment efficacy. Such a strategy would allow for
greater focus on formulation-driven interventions for clients
individually, while at the same time, allowing for any additional
therapeutic benefits that may be derived from being part of a group.
This would also help to ensure that clients are afforded sufficient
time to address their difficulties, something which may take longer
Table 4 Participants responses to the questionnaire about experiences of receiving therapy
Question
Strongly
agree (%)
Agree
(%)
Neutral
(%)
Disagree
(%)
Strongly
disagree (%)
The individual therapy prepared me for the group therapy 26.5 26.5 35 12 –
Since attending, I now know what I can do to help reduce my anxious feelings 21 38 23.5 12 6
There was sufficient time in sessions for my problems to be addressed 26.5 21 15 38 –
There were enough sessions for my needs 18 35 6 38 3
Listening to other group members talking about their problems was useful to me 41 38 15 6 –
I felt supported by the other group members during the sessions 26.5 53 12 9 –
I think the therapy has improved my anxiety 18 38 32 6 6
I would recommend the therapy to others 41 32 15 9 3
Overall, the therapy was helpful to me 29 44 15 9 3
Table 5 Supplementary analysis using participants who attended < or ≥ 50% of the total treatment sessions prior to follow-up 1 and 2
Group
Treatment arm, mean (s.d.) Waiting list, mean (s.d.) Adjustedmean differencea (95% CI), P
Hamilton Rating Scale for Anxiety
Follow-up 1
<50% sessions 18.2 (6.91), n=3 16.3b (7.74), n=25 −3.38 (−7.03, 0.27), 0.08
≥50% sessions 14.5 (8.21), n=17
Follow-up 2
<50% sessions 13.3b (8.57), n=22 13.0 (3.46), n=3
≥50% sessions 13.7 (5.64), n=20
aResulting from an ANCOVA including baseline score.
bMean calculated using subgroup sample size not split by session attendance.
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for some people with ASDs. Third, participants asked for more
innovative homework options, using technology. This may have a
positive impact upon engagement. Finally, there were some
participants who found taking part in group-based psychological
therapy difficult, which appeared to be associated with difficulties
with social communication, coupled with marked anxiety pro-
blems. It would be important to consider within any future trial
whether group-based interventions are appropriate for all partici-
pants, and while the aforementioned strategy of alternating
between individual and group-based sessions may be helpful, it
may be the case that for some people with ASDs, group-based
interventions are unlikely to be helpful, considering their difficul-
ties, and such individuals should be offered individual sessions
exclusively.
It is important to mention some of the strengths and
weaknesses associated with this trial. First, dealing with
strengths, the design and methodology were very robust: all of
the assessors were masked, and the intervention was standar-
dised. Randomisation and the data were handled independently,
while the analysis was undertaken by a statistician masked to
subgroup and using the intention-to-treat principle. Participants
were drawn from a range of sources and all had a confirmed
diagnosis of an ASD along with comorbid problems with anxiety.
It was also helpful to have interviewed participants about their
views of therapy, providing information to inform a definitive
trial. Turning to weaknesses, the current design ensured that
all participants received treatment within the context of the
research study. Such a design though, as mentioned above, may
have led to ‘spontaneous recovery’ within this study. A parallel
design, incorporating an attention-control condition, may
have been more appropriate and should be considered for
definitive trials.
Finally, recently published National Institute for Health and
Care Excellence (NICE) guidelines29 called for greater support and
service planning for those with ASDs, and despite the high
prevalence of affective disorders in this population, there are no
known definitive trials investigating the efficacy of psychological
interventions for this population. The research recommendations
made as part of the NICE guidelines29 suggested that trials of CBT
for people with ASDs needed to consider the delivery method and
duration of the intervention, and should test novel treatments in a
series of pilot studies, leading to the development of definitive
trials. The current study has addressed some of these recom‐
mendations, and a large-scale definitive trial, incorporating the
changes to treatment as outlined, is now needed to determine
whether treatment is effective. We are currently planning such
a trial.
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